63f6d3e9-3f4b-44fa-8e48-980c70b7e4f1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.500
- MITOTIC_SPINDLE+0.400
- MYC_TARGETS_V2+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- PROTEIN_SECRETION+0.300
- ALLOGRAFT_REJECTION+0.200
- DNA_REPAIR+0.200
- MTORC1_SIGNALING+0.200
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- ADIPOGENESIS-0.400
- BILE_ACID_METABOLISM-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- FATTY_ACID_METABOLISM-0.300
- HEDGEHOG_SIGNALING-0.300
- HYPOXIA-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07C-01A-11R-A034-07 | — | E | 0.881 |
| 2 | 242a1034-4aae-46f8-a40d-91710af30d0a | — | — | 0.847 |
| 3 | 0f095e03-de38-4be9-874c-c58893e031d9 | — | — | 0.830 |
| 4 | TCGA-AR-A0U2-01A-11R-A109-07 | — | B | 0.823 |
| 5 | BS_TV5B86ZD | Embryonal tumors | — | 0.822 |
| 6 | SRR11296736 | — | — | 0.821 |
| 7 | SRR650141 | — | — | 0.819 |
| 8 | BS_S6S7SK3P | high-grade glioma | — | 0.819 |
| 9 | BS_8GW1TMV2 | medulloblastoma | — | 0.818 |
| 10 | TCGA-44-7669-01A-21R-2066-07 | — | cohortA3 | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |